Skip to content

Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma

An Online Intervention for Skin Self-Checks Among Individuals at Increased Risk for Melanoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03725449
Enrollment
116
Registered
2018-10-31
Start date
2018-11-03
Completion date
2020-08-29
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysplastic Nevus, Health Status Unknown, Melanoma, No Evidence of Disease

Brief summary

This trial studies an internet-based intervention for skin self-examination (SSE) in participants at increased risk for melanoma. Early detection of suspicious growths on the skin can be done by performing regular SSE checks. Using an internet-based intervention, such as mySmartCheck, may help to promote regular, thorough checks on the skin in individuals at increased risk for melanoma.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the impact of mySmartCheck versus usual care on skin-self-examination (SSE) behaviors among individuals at increased risk for developing melanoma. SECONDARY OBJECTIVES: I. To evaluate the impact of mySmartCheck versus usual care on patients barriers and benefits to conducting SSE, SSE self-efficacy (confidence), level of worry about developing melanoma, and number of health care consultations (visits, telephone calls, and emails). II. To evaluate whether mySmartCheck effects are moderated by the patient's Total Body Photography (TBP) status. III. To identify barriers and facilitators to using mySmartCheck. OUTLINE: PHASE I: Participants complete a telephone based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability. PHASE II: Participants are randomized to 1 of 2 groups. Both the intervention and control group complete a baseline survey as well as a 13 weeks post-baseline survey. GROUP I: After completing the baseline survey, participants receive access to the mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline. GROUP II: After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline. Study duration is 13 weeks for all participants.

Interventions

OTHERBest Practice

Receive standard of care

BEHAVIORALmySmartCheck

Receive access to mySmartcheck program

OTHERSurvey Administration

Ancillary studies

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes

Inclusion criteria

* At increased risk for melanoma due to a personal history of treated melanoma without current evidence of disease, a family history of melanoma in a first-degree relative, and/or having a high-risk mole phenotype (i.e., \>= 50 normal moles or \>= 1 abnormal mole \[dysplastic nevus\]). * Access to a computer connected to the Internet. * Not adherent to SSE recommendations (i.e., did not conduct a thorough SSE during each of the previous 3 months). * Able to speak and read English. * Able to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Performance of thorough skin-self examination (SSE)Up to 13 weeksThorough SSE is defined as thoroughly examining each area of the body during the most recent SSE skin self-check in the past 2 months

Secondary

MeasureTime frameDescription
Number of SSEs performed (regardless of thoroughness)Up to 13 weeksThe total number of self-reported SSEs performed (regardless of their thoroughness)
Number of body areas examined during SSEUp to 13 weeksThe number of body areas (out of 15 total) examined during each SSE will be recorded.
Benefits to SSEUp to 13 weeksThe impact of mySmartCheck on patients' benefits to conducting SSE will be examined using 7 items.
Barriers to SSEUp to 13 weeksThe impact of mySmartCheck on patients' barriers to conducting SSE will be examined using 10 items.
Performance of thorough SSE in the past 1 monthUp to 13 weeksThorough SSE is defined as thoroughly examining each area of the body during the most recent SSE skin self-check in the past 1 month
Level of worry about melanomaUp to 13 weeksThe impact of mySmartCheck on patients' level of worry about melanoma will be examined using 2 items.
Number of health care consultationsUp to 13 weeksSurvey questions will ask about the number of health care consultations related to skin cancer surveillance in the past 3 months. Questions will include consultation reasons and outcomes.
Barriers and facilitators to using mySmart checkUp to 13 weeksThree multi-item scales will be used to measure barriers and facilitators to using the mySmartCheck program. The first scale is 15 items (5-point response scale from not at all to a lot) adapted from The Internet Impact and Effectiveness Questionnaire. This scale measures patients' perceptions of an Internet intervention in terms of the program's effectiveness in resolving their targeted health condition. The second scale includes 18 items (3-point response scale from not a problem to a major problem) adapted from the Internet Intervention Adherence Questionnaire. This scale is used to identify obstacles and barriers that interfere with using Internet intervention programs. The final scale includes 13 items (4-point response scale from not at all to very) adapted from the Internet Evaluation and Utility Questionnaire. This scale measures patients' experiences and perceptions of an Internet intervention.
SSE self-efficacyUp to 13 weeksThe impact of MySmartCheck on patient's SSE self-efficacy will be examined using 9 items.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026